Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 280-734-8 | CAS number: 83763-48-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From June 06, 1990 to Aug. 03, 1990
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 990
- Report date:
- 1990
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- Adopted : 24 February 1987
- Deviations:
- yes
- Remarks:
- No certificate of analysis and details on test substance available.
- Principles of method if other than guideline:
- Acute oral toxicity or LD50 value was determined by oral administration of test substance to male and female rats. Subsequently, observations of effects such as clinical signs and mortality were made for 14 days. At the end of observation period, all surviving animals were necropsied.
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- (according to OECD principles of GLP)
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- (3-ammonio-4-methoxyphenyl)(2-hydroxyethyl)ammonium sulphate
- EC Number:
- 280-734-8
- EC Name:
- (3-ammonio-4-methoxyphenyl)(2-hydroxyethyl)ammonium sulphate
- Cas Number:
- 83763-48-8
- Molecular formula:
- C9H14N2O2.H2O4S
- IUPAC Name:
- (3-ammonio-4-methoxyphenyl)(2-hydroxyethyl)ammonium sulphate
- Reference substance name:
- Lehmann Blau
- IUPAC Name:
- Lehmann Blau
- Reference substance name:
- 2-amino-4-hydroxyethylaminoanisole sulfate
- IUPAC Name:
- 2-amino-4-hydroxyethylaminoanisole sulfate
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material: Lehmannblausulfat; 2- amino-4-hydroxyethylaminoanisole sulfate
- Substance type: Pure active substance
- Physical state: Grey powder
- Stability under test conditions: Stable
- Storage condition of test material: Ambient, in dark
Constituent 1
Constituent 2
Constituent 3
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: not specified
- Expiration date of the lot/batch: not specified
- Purity test date: not specified
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: At ambient temperature
- Stability under test conditions: stable
- Solubility and stability of the test substance in the solvent/vehicle: 1.5% to 10% in aqua deion
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: not specified
- Preliminary purification step (if any): not specified
- Final dilution of a dissolved solid, stock liquid or gel: 1.5 to 10% in aquia deion
- Final preparation of a solid: not specified
Test animals
- Species:
- mouse
- Strain:
- other: BOR: NMRI, white mice
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Firma Winkelmann, Versuchstierzucht, Borchen
- Age at study initiation: Not reported
- Weight at study initiation: Males: 24.8 - 37.8 g; Females: 21.7 - 29.4 g
- Fasting period before study: Animals were fasted from 16 hours before until 3-4 hours after administration of the test substance.
- Housing: Collectively housed up to a maximum of 5 animals per cage (Makrolon type III).
- Diet: Ssniff- R Alleindiet pellets; ad libitum
- Water: Drinking water as for human consumption in Makrolon drinking bottles; ad libitum
- Acclimation period: At least for 7 days
ENVIRONMENTAL CONDITIONS
- Temperature: 21 ± 2°C
- Relative humidity: 50 - 85 % (measured with thermohygrometer twice daily)
- Air changes: Not reported
- Photoperiod: 12 hours dark / 12 hours light, artificial lighting (120 lux) from 7.00 a.m. - 7.00 p.m.
EXPERIMENT INITIATION DATE: June 26, 1990
EXPERIMENT COMPLETION DATE: Aug. 03, 1990
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: Aqua deion
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 1.25 - 10%
MAXIMUM DOSE VOLUME APPLIED:0.38 mL
ADMINISTRATION OF TEST SUBSTANCE: A single oral administration of the test substance was performed by gavage using a stomach tube
- Rationale for the selection of the starting dose: Based on the results of range finding study doses for main study were selected. - Doses:
- 125, 250, 500, 750 and 1000 mg/kg bw.
- No. of animals per sex per dose:
- 5 animals/sex/dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical observations were conducted at 10 min and 1, 2, 6, 24 hours and thereafter once daily up to Day 14. Body weights were measured at Days 0, 7 and 14.
- Necropsy of survivors performed: Yes, surviving animals were sacrificed by cervical dislocation after 14 days and gross pathological examinations were subsequently performed.
Results and discussion
- Preliminary study:
- A preliminary range finding test with dose of 2000 mg/kg bw was conducted on 2 female mice. Both the treated mice died at 2000 mg/kg bw.
Effect levelsopen allclose all
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 327 mg/kg bw
- Based on:
- act. ingr.
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 333 mg/kg bw
- Based on:
- act. ingr.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 351 mg/kg bw
- Based on:
- act. ingr.
- Mortality:
- The following mortalities were observed within 24-72 hours after dosing:
1) At 125 mg/kg: 1/5 males and 1/5 females
2) At 250 mg/kg: 2/5 males and 1/5 females
3) At 500 mg/kg : 4/5 males and 3/5 females
4) At 750 mg/kg: 3/5 males and 5/5 females
5) At 1000 mg/kg: 5/5 males and 4/5 females
Details of pre-terminal deaths were provided in the table 2 under ‘Any other information on results incl. tables’ - Clinical signs:
- other: Severe clinical symptoms related to CNS symptoms, coordination, reflexes and autonomic functions were observed with dose related intensity as follows: 1) At 125 mg/kg: Decreased activity and pilorection 2) At 250 mg/kg: Decreased activity, ventral positi
- Gross pathology:
- Gross pathological examinations at 14 days post administration (terminal necropsies) revealed no test substance-dependent findings. The macroscopic changes observed were attributable to the sacrificing procedure or to minor variations which often occur spontaneously in mice of this strain. However, all dose animals killed in extremis or died spontaneously revealed alterations which were considered to be test substance-related.
Details of necropsy findings were provided in the table 2 under ‘Any other information on results incl. tables’.
Any other information on results incl. tables
Table 1: Cumulative table of pre-terminal deaths (Study# 71231)
Group |
Dose (mg/kg) |
No. of animals |
Post-treatment time |
|||||
24 hours |
7 days |
14 days |
||||||
m |
f |
m |
f |
m |
f |
|||
I |
125 |
5m + 5f |
0/5 |
0/5 |
1/5 |
1/5 |
1/5 |
1/5 |
II |
250 |
5m + 5f |
0/5 |
0/5 |
2/5 |
1/5 |
2/5 |
1/5 |
III |
500 |
5m + 5f |
1/5 |
0/5 |
4/5 |
3/5 |
4/5 |
3/5 |
IV |
750 |
5m + 5f |
1/5 |
0/5 |
3/5 |
5/5 |
3/5 |
5/5 |
V |
1000 |
5m + 5f |
1/5 |
1/5 |
5/5 |
4/5 |
5/5 |
4/5 |
Table 2: Summary of Necropsy findings (Study# 71231)
Dose group |
Time point post dose |
Specific findings |
125 mg/kg |
72 hours |
Hyperemic and dilated stomach and intestine, pale discoloration of spleen, reduced size of spleen, hyperemic kidney |
14 days |
Pale discoloration of kidney, thick skinned surface hyperemic pelvis |
|
250 mg/kg |
48 hours |
None |
14 days |
Dark discoloration of kidney |
|
500 mg/kg |
24-48 hours |
Blue discoloration and hyperemic stomach, hyperemic intestine, dark discoloration of liver, pale discoloration and reduced size of spleen, hyperemic kidney, hydrometra of genital system |
14 days |
Hyperemic kidney |
|
750 mg/kg |
24-72 hours |
Blue discoloration and hyperemic stomach, dilated intestine, pale discoloration of spleen, pale discoloration and hyperemic pelvis |
14 days |
Pale discoloration of liver, spleen, kidney |
|
1000 mg/kg |
24-48 hours |
Blue discoloration and hyperemic stomach and intestine, dark discoloration of liver, pale discoloration of spleen, redden and blue dark discoloration of pelvis |
14 days |
Pale discoloration of kidney |
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- Acute oral administration of Lehmannblau sulfat (2- amino-4-hydroxyethylaminoanisole sulfate) to male and female mice resulted in a LD50 value of 327 mg/kg (Male LD50: 333 mg/kg; female LD50: 351 mg/kg). The registered substance is classified as Category 4 according to GHS regulation.
- Executive summary:
The purpose of this study was to determine the acute oral toxicity (LD50) of Lehmannblau sulfat (2- amino-4-hydroxyethylaminoanisole sulfate) when administered once orally to male and female mice.
BOR: NMRI white mice were used in this study. Test substance was administered by gavage using a stomach tube at dose levels of 125, 250, 500, 750 and 1000 mg/kg bw. The dose levels were based on the results of a range finding study where a dose of 2000 mg/kg bw was administered to 2 female animals and both animals died 24 hours post dosing.
Clinical observations were conducted at regular intervals during the 14-day observation period. Body weights were measured at Days 0, 7 and 14. Animals found dead or killed in extremis were immediately necropsied.
The test substance caused dose related clinical signs increasing in severity to CNS, coordination, reflexes and autonomic functions up to 72 hours after dosing. Weight gains were reduced in all surviving animals.
Out of 10 animals (5 males and 5 females), only 1 female survived at 1000 mg/kg bw. At 750 mg/kg bw, only 2 male animals survived. One male animal and 2 female animals survived at 500 mg/kg bw. At 250 mg/kg bw, the mortality rate was low and 4 female and 3 male animals survived. 4 animals/sex survived at 125 mg/kg. Gross pathological examinations at 14 days post administration (terminal necropsies) revealed no test substance-dependent findings in any of the dose groups.
Based on the observed mortality, the following LD50 figures were determined at 14 days according to Finney:
LD50 mouse, female: 351 mg/kg bw
LD50 mouse, male: 333 mg/kg bw
LD50 mouse male + female: 327 mg/kg bw
Acute oral administration of Lehmannblau sulfat (2- amino-4-hydroxyethylaminoanisole sulfate) to male and female mice resulted in a LD50 value of 327 mg/kg (Male LD50: 333 mg/kg; female LD50: 351 mg/kg). The registered substance is classified as Category 4 according to GHS regulation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.